Author(s)

Mohsin Ahmed^1*, Golam Morshed², Mahmood Hasan Khan³, Md. Arifur Rahman², Muhammed Aminur Razzaque¹, Shariful Islam¹, Sayeedur Rahman Khan¹, Chowdhury Md. Kudrat-E-Khuda¹, Salahuddin Anis Shiblee⁴, Md. Habibur Rahman⁴

¹Department of Cardiology, National Institute of Cardiovascular Diseases, Dhaka, Bangladesh.
²Department of Cardiology, Government Employee’s Hospital, Dhaka, Bangladesh.
³Department of Cardiology, Delta Hospital Ltd., Dhaka, Bangladesh.
⁴IPDI Foundation, Dhaka, Bangladesh.

Objective: This study aimed to evaluate the efficacy of trimetazidine on exercise capacity via a six-minute walk test in patients with ischaemic cardiomyopathy and also evaluate the effect of trimetazidine on left ventricular function via echocardiography in the same population. Methods: This prospective observational study, conducted at the National Institute of Cardiovascular Diseases in Dhaka, Bangladesh, enrolled 200 patients with ischaemic cardiomyopathy and a depressed left ventricular ejection fraction (LVEF < 35%). We investigated the effects of modified-release trimetazidine on exercise capacity and left ventricular function in ischaemic cardiomyopathy patients with an LVEF less than 35%. The cohort, was divided into Group 1, which received modified-release trimetazidine alongside standard anti-ischaemic therapy and Group 2, which received standard therapy. Patients were subjected to a year-long study with follow-ups at the 1st and 6th months. Using SPSS software, statistical analysis was used to assess treatment-related effects and baseline comparability. Results: In this study (n = 200) of ischaemic cardiomyopathy patients, the mean age was 58 years, with 76% of the patients being male. All study subjects received GDMT (Guideline-Directed Medical Therapy) for angina and heart failure. Those who received the modified released form of trimetazidine developed lesions during the 1st and 2nd follow-ups, during which the LVEF, LVIDd, and six-minute walk distance significantly improved (p < 0.05). There was a progressive improvement in functional status, which was statistically highly significant at the second follow-up. Conclusion: The findings of the present study demonstrated that the addition of modified-release trimetazidine to GDMT can improve exercise capacity and left ventricular function in patients with ischaemic cardiomyopathy.

Bangladesh, Heart Failure, Exercise Capacity, Trimetazidine, Ischaemic Cardiomyopathy

Ahmed, M. , Morshed, G. , Khan, M. , Rahman, M. , Razzaque, M. , Islam, S. , Khan, S. , Kudrat-E-Khuda, C. , Shiblee, S. and Rahman, M. (2024) Effect of Trimetazidine on Functional Capacity in Patient with Ischaemic Cardiomyopathy (TOFCAPI). International Journal of Clinical Medicine, 15, 55-67. doi: 10.4236/ijcm.2024.152004.